CD19 and colorectal carcinoma: The percentage of CD19+CD20−CD38high cells was 1.4% of CD19+ lymphocytes in PBMCs of healthy controls compared to 12.6% in PBMCs and 31.7% in the tumor tissue of CRC patients (p<0,005, Fig.2A).